Find, compare & contact
Imitrex (Sumatriptan Succinate) API Manufacturers & Suppliers

Looking for Sumatriptan Succinate API 103628-46-2?

Description:

Here you will find a list of producers, manufacturers and distributors of Sumatriptan Succinate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Sumatriptan Succinate 

Synonyms:

Imigran , Imitrex , NP101 , Sumatran , Sumatriptan , Sumatriptan Succinate , Sumatriptanum , Sumax , triptan , Sumatriptan succinate  

Cas Number:

103628-46-2 

DrugBank number:

DB00669 

Unique Ingredient Identifier:

8R78F6L9VO

Sumatriptan Succinate is a type of Selective 5HT1-agonists

Selective 5HT1-agonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various neurological and psychiatric disorders. These compounds specifically target and activate the 5HT1 receptor subtype, which belongs to the serotonin (5-hydroxytryptamine) receptor family. The 5HT1 receptor is primarily found in the central nervous system and is involved in regulating neurotransmitter release, mood, pain perception, and vasoconstriction.

Selective 5HT1-agonists have demonstrated therapeutic potential in the management of several conditions, including migraines, cluster headaches, and depression. By binding to and activating the 5HT1 receptor, these APIs can modulate serotonin levels in the brain, leading to a cascade of neurochemical events that alleviate symptoms associated with these disorders.

One of the key advantages of selective 5HT1-agonists is their targeted action, focusing specifically on the 5HT1 receptor without significant interactions with other receptor subtypes. This selectivity reduces the risk of adverse effects and improves the overall safety profile of these APIs.

Moreover, selective 5HT1-agonists often exhibit high affinity for the 5HT1 receptor, enhancing their efficacy and therapeutic potential. Through their agonistic activity, these compounds can regulate the release of neurotransmitters and modulate pain pathways, offering relief to patients suffering from debilitating migraines or cluster headaches.

In summary, selective 5HT1-agonists are a valuable subcategory of pharmaceutical APIs that provide targeted and effective treatment options for various neurological and psychiatric disorders. Their ability to selectively activate the 5HT1 receptor offers therapeutic benefits with reduced side effects, making them an essential component in the management of conditions such as migraines, cluster headaches, and depression.

Sumatriptan Succinate (Selective 5HT1-agonists), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Hari Ganesh Pharma Private Limited from India, product country of origin India
• LGM Pharma from United States, product country of origin World
• Natco Pharma from India, product country of origin India
• Phalanx Labs from India, product country of origin India
• Vamsi Labs from India, product country of origin India
• Asymchem from China, product country of origin China
• Aquatic Remedies Pvt Ltd from India, product country of origin India
• Dr. Reddy's from India, product country of origin India
• Kolon Life Science from South Korea, product country of origin South Korea
• Quimica Sintetica from Spain, product country of origin Unknown
• MSN Pharma from India, product country of origin India
• Mylan from India, product country of origin India
• Lupin from India, product country of origin India
• Moehs from Spain, product country of origin Spain
• Sun Pharma from India, product country of origin India
• Cipla from India, product country of origin India
• Divis Labs. from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.